Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)

Davies, Kalatu R.; Brewster, Abenaa M.; Bedrosian, Isabelle; Parker, Patricia A.; Crosby, Melissa A.; Peterson, Susan K.; Shen, Yu; Volk, Robert J.; Cantor, Scott B.

doi:10.1186/s13058-016-0752-y

Table 3 Predicted Differences in Quality-Adjusted Life Expectancy by Degree of Family History of Breast Cancer

From: Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)

Patient and Disease Characteristics			Quality-Adjusted Life-Years
			No Family History			Breast Cancer in a Second-Degree Relative			Breast Cancer in a First-Degree Relative
			No Family History			Breast Cancer in a Second-Degree Relative			Unilateral			Bilateral
Age (years)	ER Status	Stage	No CPM	CPM	Δ	No CPM	CPM	Δ	No CPM	CPM	Δ	No CPM	CPM	Δ
40	Positive	I	34.61	34.70	0.09	34.56	34.70	0.14	34.45	34.70	0.25	34.16	34.68	0.52
40	Negative	I	34.48	34.60	0.12	34.43	34.60	0.17	34.28	34.59	0.31	33.92	34.57	0.65
40	Positive	II	27.42	27.45	0.03	27.38	27.45	0.07	27.28	27.44	0.16	27.04	27.43	0.40
40	Negative	II	27.33	27.41	0.08	27.28	27.41	0.13	27.18	27.40	0.23	26.89	27.39	0.50
40	Positive	III	15.45	15.42	-0.03	15.42	15.42	0.00	15.38	15.41	0.03	15.28	15.41	0.14
40	Negative	III	15.36	15.36	0.01	15.33	15.36	0.03	15.27	15.36	0.09	15.12	15.34	0.22
50	Positive	I	26.92	26.97	0.05	26.88	26.97	0.09	26.79	26.96	0.17	26.58	26.95	0.38
50	Negative	I	26.94	27.03	0.09	26.89	27.03	0.14	26.78	27.02	0.25	26.52	27.01	0.49
50	Positive	II	21.65	21.66	0.02	21.62	21.66	0.05	21.55	21.66	0.11	21.38	21.65	0.27
50	Negative	II	21.61	21.65	0.05	21.57	21.65	0.09	21.50	21.65	0.15	21.29	21.63	0.34
50	Positive	III	12.57	12.52	-0.05	12.55	12.52	-0.03	12.52	12.52	0.00	12.43	12.52	0.08
50	Negative	III	12.53	12.49	-0.04	12.51	12.49	-0.02	12.47	12.49	0.02	12.36	12.49	0.13
60	Positive	I	19.85	19.84	-0.01	19.82	19.84	0.01	19.76	19.83	0.07	19.61	19.83	0.21
60	Negative	I	19.87	19.88	0.01	19.83	19.88	0.05	19.76	19.88	0.12	19.58	19.87	0.28
60	Positive	II	16.12	16.10	-0.02	16.10	16.10	0.00	16.06	16.10	0.04	15.93	16.09	0.17
60	Negative	II	16.17	16.15	-0.02	16.15	16.15	0.00	16.10	16.15	0.05	15.97	16.14	0.17
60	Positive	III	9.88	9.82	-0.06	9.87	9.81	-0.05	9.84	9.81	-0.03	9.78	9.81	0.03
60	Negative	III	9.80	9.76	-0.04	9.79	9.76	-0.03	9.75	9.76	0.01	9.68	9.75	0.07
70	Positive	I	13.38	13.34	-0.05	13.37	13.34	-0.03	13.33	13.33	0.00	13.25	13.33	0.08
70	Negative	I	13.34	13.30	-0.03	13.32	13.30	-0.02	13.28	13.30	0.02	13.18	13.29	0.11
70	Positive	II	11.18	11.12	-0.06	11.16	11.12	-0.05	11.13	11.12	-0.01	11.06	11.12	0.05
70	Negative	II	11.18	11.13	-0.05	11.16	11.13	-0.03	11.12	11.13	0.01	11.03	11.12	0.09
70	Positive	III	7.24	7.16	-0.08	7.24	7.16	-0.07	7.22	7.16	-0.06	7.18	7.16	-0.02
70	Negative	III	7.24	7.17	-0.07	7.23	7.17	-0.06	7.22	7.17	-0.05	7.18	7.17	-0.01

ER estrogen receptor, CPM contralateral prophylactic mastectomy, Δ, difference (CPM-No CPM); CBC risk reduction = 95% (base-case)

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us